US › Healthcare

Purple Biotech (PPBT)

US · Healthcare · Biotechnology

$1.54+0.98%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$441,000

EPS

$1.07

EPS estimate

$-0.98

EPS came in at 1.07 against a street estimate of -0.98 — a beat of 209.2%.

Key statistics

Market cap

$2.9M

Forward P/E

0.0

P/B

0.23

Book value

$12.00

EPS (TTM)

$-47.64

52-week high

$14.10

52-week low

$1.16

50-day MA

$1.56

200-day MA

$4.05

Beta

-0.53

Analyst view

Analysts rate Purple Biotech a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $17.00.

Shareholding

Insiders

3.73%

Institutions

7.10%

Largest institutional holders

Fund	Stake
Susquehanna International Group, LLP	3.28%
SmartHarvest Portfolios, LLC	1.75%
Citadel Advisors Llc	0.81%
BNP Paribas Arbitrage, SA	0.12%
SRS Capital Advisors Inc	0.09%
Rhumbline Advisers	0.04%
SIMPLEX TRADING, LLC	0.04%
Morgan Stanley - Brokerage Accounts	0.04%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Purple Biotech — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.